Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Enovix Q3 GAAP EPS of $0.19, revenue of $11M (SeekingAlpha) +++ ENOVIX Aktie -3,30%

CAPRICOR THERAPEUTICS Aktie

 >Aktienkurs 
5.874 EUR    -4.5%    (TradegateBSX)
Ask: 5.91 EUR / 1700 Stück
Bid: 5.836 EUR / 1800 Stück
Tagesumsatz: 3823 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -8,8%
1 Monat: -16,0%
3 Monate: -65,0%
6 Monate: -78,8%
1 Jahr: +5,4%
laufendes Jahr: -75,6%
>CAPRICOR THERAPEUTICS Aktie
Name:  CAPRICOR THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US14070B3096 / A2PLU4
Symbol/ Ticker:  4LN2 (Frankfurt) / CAPR (NASDAQ)
Kürzel:  FRA:4LN2, ETR:4LN2, 4LN2:GR, NASDAQ:CAPR
Index:  -
Webseite:  https://capricor.com/
Profil:  Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases. Its lead program, Deramiocel, is an allogeneic cardiac-derived cell therapy being advanced for Duchenne mu..
>Volltext..
Marktkapitalisierung:  406.42 Mio. EUR
Unternehmenswert:  277.68 Mio. EUR
Umsatz:  -
EBITDA:  -118.8 Mio. EUR
Nettogewinn:  -115.54 Mio. EUR
Gewinn je Aktie:  -2.19 EUR
Schulden:  81.28 Mio. EUR
Liquide Mittel:  18.69 Mio. EUR
Operativer Cashflow:  -92.84 Mio. EUR
Bargeldquote:  7.22
Umsatzwachstum:  -100%
Gewinnwachstum:  -90.76%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CAPRICOR THERAPEUTICS, CAPRICOR THERAPEUTIC
Letzte Datenerhebung:  14.10.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 58.14 Mio. St.
Frei handelbar: 90.56%
Leerverk. Aktien: 32.38%
Rückkaufquote: -55.44%
Mitarbeiter: 231
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Buy
Kursziel: 332.33%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 1.87
PEG-Ratio: -0.06
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -51.53%
Eigenkaprendite: -73.7%
>Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten
 
05.10.26 - 15:01
 Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress (GlobeNewswire EN)
 
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year-...
28.09.26 - 08:12
 Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
 
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......
28.09.26 - 08:12
 CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (PR Newswire)
 
LOS ANGELES, Sept. 28, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a)......
25.09.26 - 18:21
 CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline (PR Newswire)
 
SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......
24.09.26 - 23:45
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR (PR Newswire)
 
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......
24.09.26 - 18:03
 CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead......
24.09.26 - 18:01
 CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline (PR Newswire)
 
SAN FRANCISCO, Sept. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......
24.09.26 - 16:12
 SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR (PR Newswire)
 
Wall Street's view of Capricor Therapeutics reversed within hours after FDA briefing documents allegedly exposed unagreed changes to the HOPE-3 statistical analysis plan, with analysts questioning data integrity as CAPR shares fell 78.7%. NEW YORK, Sept. 24, 2026 /PRNewswire/ -- SueWallSt......
23.09.26 - 16:09
 CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky (PR Newswire)
 
From Optimism to Disillusionment: Capricor Therapeutics investors watched sentiment collapse from confidence in an August 22, 2026 approval date to a 78.7% share decline after FDA briefing documents allegedly surfaced undisclosed statistical analysis plan changes. NEW YORK, Sept. 23, 2026......
22.09.26 - 12:42
 CAPR Class Action: Capricor Therapeutics Investors are Notified of the Upcoming September 28 Deadline in Ongoing Securities Fraud Class Action over Clinical Data (PR Newswire)
 
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Sept. 22, 2026 /PRNewswire/ -- Leading securities law firm......
22.09.26 - 09:42
 CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (PR Newswire)
 
LOS ANGELES, Sept. 22, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a)......
22.09.26 - 07:21
 Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
 
NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......
22.09.26 - 00:21
 1 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until Monday, September......
21.09.26 - 18:15
 CAPR 1-WEEK DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline (PR Newswire)
 
SAN FRANCISCO, Sept. 21, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......
19.09.26 - 04:06
 Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR (PR Newswire)
 
NEW ORLEANS, Sept. 18, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or the......
19.09.26 - 01:09
 Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline (PR Newswire)
 
SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26,......
18.09.26 - 19:03
 Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
LOS ANGELES, Sept. 18, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Capricor Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR CAPRICOR THERAPEUTICS, INC. INVESTMENTS,......
18.09.26 - 00:21
 Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline (PR Newswire)
 
SAN FRANCISCO, Sept. 17, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......
17.09.26 - 19:06
 Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
BENSALEM, Pa., Sept. 17, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Capricor Therapeutics, Inc. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR......
17.09.26 - 16:09
 CAPR Deadline Alert: SueWallSt Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Securities Class Action Deadline on September 28, 2026 (PR Newswire)
 
A securities class action alleges Capricor Therapeutics did not follow the pre-specified blinding and protocol procedures for its Phase 3 HOPE-3 trial, with FDA later noting that the final study protocol deviated from the associated statistical analysis plan. NEW YORK, Sept. 17, 2026......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Man sollte niemals vergessen: auch Damen gehören zu den Weibern. - Peter Bamm
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!